Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDFATHER-NSCLC-02: Visugromab plus nivolumab ± docetaxel versus docetaxel in second-line metastatic non-squamous NSCLC
2024-516794-70-00Phase 2Authorised
- Sponsor
- CatalYm
- Start
- Oct 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in non-squamous non-small cell lung cancer comparing Visugromab + nivolumab, Visugromab + nivolumab + docetaxel and Docetaxel monotherapy (3 arms). Primary endpoint: Objective response rate (ORR). Planned start Oct 2025; status: authorised.
02
Drugs
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on 2024-516794-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516794-70-00.